Carolin Kröner1, Thomas Wittmann1, Simone Reu2, Veronika Teusch3, Mathias Klemme4, Daniela Rauch1, Meike Hengst1, Matthias Kappler1, Nazan Cobanoglu5, Tugba Sismanlar6, Ayse T Aslan6, Ilaria Campo7, Marijke Proesmans8, Thomas Schaible9, Susanne Terheggen-Lagro10, Nicolas Regamey11, Ernst Eber12, Jürgen Seidenberg13, Nicolaus Schwerk14, Charalampos Aslanidis15, Peter Lohse16, Frank Brasch17, Ralf Zarbock1, Matthias Griese1. 1. Department of Pediatric Pneumology, Dr. von Hauner Children's Hospital, LMU Munich, Munich, Germany. 2. Department of Pathology, LMU Munich, Munich, Germany. 3. Department of Pediatric Radiology, Dr. von Hauner Children's Hospital, LMU Munich, Munich, Germany. 4. Department of Neonatology, Klinikum Großhadern, LMU Munich, Munich, Germany. 5. Department of Pediatric Pneumonology, Ankara University Children's Hospital, Ankara University, Ankara, Turkey. 6. Gazi University Hospital, Ankara University, Ankara, Turkey. 7. Pneumology Unit, IRCCS San Matteo Hospital Foundation and University of Pavia, Pavia, Italy. 8. Department of Pediatric Pneumology, University Hospital Leuven, University Leuven, Leuven, Belgium. 9. Department of Neonatology, University Hospital, University Mannheim, Mannheim, Germany. 10. Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands. 11. Department of Pediatric Pneumology, Children's Hospital, Lucerne, Switzerland. 12. Department of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology and Allergology, Medical University of Graz, Graz, Austria. 13. Department of Pediatric Pneumology and Allergology, Neonatology and Intensive Care, Klinikum Oldenburg, Medical Campus of University Oldenburg, Oldenburg, Germany. 14. Clinic of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany. 15. Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Regensburg, Germany. 16. Hohentwielstr. 32, 78250 Tengen, Germany. 17. Department of Pathology, Academic Teaching Hospital Bielefeld, Bielefeld, Germany.
Abstract
BACKGROUND: Knowledge about the clinical spectrum of lung disease caused by variations in the ATP binding cassette subfamily A member 3 (ABCA3) gene is limited. Here we describe genotype-phenotype correlations in a European cohort. METHODS: We retrospectively analysed baseline and outcome characteristics of 40 patients with two disease-causing ABCA3 mutations collected between 2001 and 2015. RESULTS: Of 22 homozygous (15 male) and 18 compound heterozygous patients (3 male), 37 presented with neonatal respiratory distress syndrome as term babies. At follow-up, two major phenotypes are documented: patients with (1) early lethal mutations subdivided into (1a) dying within the first 6 months or (1b) before the age of 5 years, and (2) patients with prolonged survival into childhood, adolescence or adulthood. Patients with null/null mutations predicting complete ABCA3 deficiency died within the 1st weeks to months of life, while those with null/other or other/other mutations had a more variable presentation and outcome. Treatment with exogenous surfactant, systemic steroids, hydroxychloroquine and whole lung lavages had apparent but many times transient effects in individual subjects. CONCLUSIONS: Overall long-term (>5 years) survival of subjects with two disease-causing ABCA3 mutations was <20%. Response to therapies needs to be ascertained in randomised controlled trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
BACKGROUND: Knowledge about the clinical spectrum of lung disease caused by variations in the ATP binding cassette subfamily A member 3 (ABCA3) gene is limited. Here we describe genotype-phenotype correlations in a European cohort. METHODS: We retrospectively analysed baseline and outcome characteristics of 40 patients with two disease-causing ABCA3 mutations collected between 2001 and 2015. RESULTS: Of 22 homozygous (15 male) and 18 compound heterozygous patients (3 male), 37 presented with neonatal respiratory distress syndrome as term babies. At follow-up, two major phenotypes are documented: patients with (1) early lethal mutations subdivided into (1a) dying within the first 6 months or (1b) before the age of 5 years, and (2) patients with prolonged survival into childhood, adolescence or adulthood. Patients with null/null mutations predicting complete ABCA3 deficiency died within the 1st weeks to months of life, while those with null/other or other/other mutations had a more variable presentation and outcome. Treatment with exogenous surfactant, systemic steroids, hydroxychloroquine and whole lung lavages had apparent but many times transient effects in individual subjects. CONCLUSIONS: Overall long-term (>5 years) survival of subjects with two disease-causing ABCA3 mutations was <20%. Response to therapies needs to be ascertained in randomised controlled trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
ABCA3; Paediatric interstitial lung disease; Surfactant protein
Authors: Richard K Albert; Bradford Smith; Carrie E Perlman; David A Schwartz Journal: Am J Respir Crit Care Med Date: 2019-07-15 Impact factor: 21.405
Authors: Tara N Rindler; Courtney A Stockman; Alyssa L Filuta; Kari M Brown; John M Snowball; Wenjia Zhou; Ruud Veldhuizen; Erika M Zink; Sydney E Dautel; Geremy Clair; Charles Ansong; Yan Xu; James P Bridges; Jeffrey A Whitsett Journal: JCI Insight Date: 2017-12-21
Authors: June Y Hu; Ping Yang; Daniel J Wegner; Hillary B Heins; Cliff J Luke; Fuhai Li; Frances V White; Gary A Silverman; F Sessions Cole; Jennifer A Wambach Journal: Hum Mutat Date: 2020-04-01 Impact factor: 4.878
Authors: Jennifer A Wambach; Ping Yang; Daniel J Wegner; Hillary B Heins; Cliff Luke; Fuhai Li; Frances V White; F Sessions Cole Journal: Am J Respir Cell Mol Biol Date: 2020-10 Impact factor: 6.914
Authors: Xin Si; Lea C Steffes; Jennifer C Schymick; Florette K Hazard; Michael C Tracy; David N Cornfield Journal: J Pediatr Date: 2020-12-24 Impact factor: 4.406